Literature DB >> 20024566

[Patient-reported and patient-weighted outcomes in ophthalmology].

F Scheibler1, R P Finger, R Grosselfinger, C-M Dintsios.   

Abstract

Considering patients' values and preferences in comparative effectiveness research (CER) is one of the main challenges in ophthalmology (value-based medicine). This article defines core terms in CER. The concept of patient-relevant (or patient-important) outcomes is distinguished from patient-reported outcomes (PRO) by means of examples in the field of ophthalmology. In order to be able to give a consistant recommendation if an intervention leads to conflicting results for different outcomes (trade-off), a ranking of outcomes will be necessary. Examples of studies in glaucoma patients are provided that demonstrate the possibilities of ranking of outcomes based on patient preferences.

Entities:  

Mesh:

Year:  2010        PMID: 20024566     DOI: 10.1007/s00347-009-2037-7

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  24 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  Views of glaucoma patients on aspects of their treatment: an assessment of patient preference by conjoint analysis.

Authors:  Jonathan S Bhargava; Bakula Patel; Alexander J E Foss; Anthony J Avery; Anthony J King
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-07       Impact factor: 4.799

3.  Factors influencing white-coat effect.

Authors:  Efstathios D Manios; Eleni A Koroboki; Georgios K Tsivgoulis; Konstantinos M Spengos; Ioanna K Spiliopoulou; Fiona G Brodie; Konstantinos N Vemmos; Nikolaos A Zakopoulos
Journal:  Am J Hypertens       Date:  2008-01-03       Impact factor: 2.689

4.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

5.  Sample size slippages in randomised trials: exclusions and the lost and wayward.

Authors:  Kenneth F Schulz; David A Grimes
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

6.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

Review 7.  Surrogate end points in clinical research: hazardous to your health.

Authors:  David A Grimes; Kenneth F Schulz
Journal:  Obstet Gynecol       Date:  2005-05       Impact factor: 7.661

8.  Views of glaucoma patients on provision of follow-up care; an assessment of patient preferences by conjoint analysis.

Authors:  J S Bhargava; A Bhan-Bhargava; A J E Foss; A J King
Journal:  Br J Ophthalmol       Date:  2008-07-29       Impact factor: 4.638

9.  Evaluation of quality of life and priorities of patients with glaucoma.

Authors:  Peter A Aspinall; Zoe K Johnson; Augusto Azuara-Blanco; Alicia Montarzino; Roger Brice; Adrian Vickers
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-05       Impact factor: 4.799

10.  Are chemotherapy patients' HRQoL importance weights consistent with linear scoring rules? A stated-choice approach.

Authors:  F Reed Johnson; A Brett Hauber; David Osoba; Ming-Ann Hsu; John Coombs; Catherine Copley-Merriman
Journal:  Qual Life Res       Date:  2006-03       Impact factor: 4.147

View more
  1 in total

1.  [Psychometric properties of the FKS : Reliability, validity, Rasch analysis, and descriptive results of the German version of the Children's Visual Function Questionnaire].

Authors:  E Farin; M Metten; M Nagl; W A Lagrèze; C Pieh-Beisse
Journal:  Ophthalmologe       Date:  2011-07       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.